Helsinn announces its support for the International Fellowship Program (IFP), a joint project founded by the Society for Translational Oncology (STO) and Chinese Society of Clinical Oncology (CSCO) 10 October 2017
Helsinn Group Announces Upcoming Presentation of Phase III data of NEPA (fosnetupitant/ palonosetron) IV at ESMO 2017 6 September 2017
Helsinn Therapeutics (U.S.) Inc., Signs Co-Promotion Agreement for Cancer Therapeutic Zykadia® in the US 5 September 2017
AMAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round 5 September 2017
Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 2 August 2017
HELSINN ADVANCED SYNTHESIS S.A. BIASCA: CONCORSO PER L’ASSEGNAZIONE DI BORSE DI STUDIO 2017/2018 7 July 2017
Linkedin